Rapid Heartbeat: Drugs That Cause or Treat It

What Counts as a Rapid Heartbeat?

A resting heart rate consistently above 100 bpm meets the clinical definition of tachycardia. The American Heart Association defines normal sinus rhythm as 60 to 100 bpm at rest, though trained athletes may sit well below 60 bpm without any pathology [1]. Heart rate is regulated by electrical signals originating in the sinoatrial (SA) node. Disruption at the SA node, the atrioventricular (AV) node, or within the ventricles produces different tachycardia subtypes.

Tachycardia is not a single diagnosis. It is a physical sign. Sinus tachycardia, the most common type, often reflects a normal physiological response to fever, dehydration, anxiety, or medication effects [2]. Supraventricular tachycardia (SVT) involves abnormal circuits above the ventricles. Ventricular tachycardia (VT) originates below the bundle of His and carries a higher risk of hemodynamic collapse. The 2015 ACC/AHA/HRS guideline for SVT management categorizes arrhythmias by mechanism and maps each to specific pharmacological therapy [3]. Drug selection depends entirely on the type.

Common Drugs That Cause Rapid Heartbeat

More than 30 widely prescribed drug classes list tachycardia as an adverse effect, and identifying the offending agent is the first step in management. Stimulant medications top the list. Amphetamine-based drugs like Adderall and lisdexamfetamine (Vyvanse) increase norepinephrine and dopamine release, raising heart rate by 5 to 10 bpm on average, with some patients exceeding 20 bpm above baseline [4]. Methylphenidate produces a similar sympathomimetic effect.

Short-acting beta-2 agonists such as albuterol, prescribed to over 25 million Americans with asthma, cause reflex tachycardia through peripheral vasodilation and direct beta-1 receptor stimulation at higher doses [5]. Pseudoephedrine and phenylephrine, available without a prescription, are alpha-adrenergic agonists that raise both blood pressure and heart rate. A 2005 meta-analysis published in the BMJ found pseudoephedrine increased heart rate by a mean of 2.83 bpm, with significantly higher effects in individuals with pre-existing cardiovascular conditions [6].

Thyroid hormone replacement also warrants attention. Levothyroxine at supratherapeutic doses mimics hyperthyroidism, producing palpitations in up to 10% of overtreated patients [7]. Atropine and other anticholinergic drugs block vagal tone, removing the parasympathetic brake on heart rate. Tricyclic antidepressants (amitriptyline, nortriptyline) carry anticholinergic and sodium channel-blocking properties, and overdose produces sinus tachycardia as an early warning sign [8].

Other notable offenders include:

• GLP-1 receptor agonists: semaglutide and liraglutide raise resting heart rate by 1 to 4 bpm on average, a class-wide effect observed in SUSTAIN and LEADER trials [9]
• Antipsychotics: clozapine-induced tachycardia occurs in 25% of patients, likely through muscarinic receptor blockade and alpha-1 antagonism [10]
• Vasodilators: minoxidil (oral) triggers reflex tachycardia and typically requires co-administration with a beta-blocker
• Caffeine and nicotine: both stimulate catecholamine release and are the most frequently consumed tachycardia-inducing substances worldwide

Beta-Blockers: The Frontline Treatment

Beta-adrenergic blockers are the most prescribed drug class for rate control, and they work by competitive antagonism at beta-1 receptors in the SA and AV nodes. The 2023 AHA/ACC/ACCP/HRS guideline for atrial fibrillation management recommends beta-blockers as first-line rate control therapy, targeting a resting heart rate below 110 bpm in the lenient control strategy [11].

Metoprolol succinate (extended-release) is the most commonly chosen agent. A typical starting dose is 25 to 50 mg daily, titrated up to 200 mg. In the MERIT-HF trial (N=3,991), metoprolol succinate reduced all-cause mortality by 34% in patients with heart failure and elevated resting heart rates [12]. Atenolol (25 to 100 mg daily) provides an alternative with once-daily dosing and minimal lipophilicity, reducing central nervous system side effects. Propranolol, a non-selective beta-blocker, is preferred for performance anxiety-related tachycardia and thyrotoxicosis because it also inhibits peripheral T4-to-T3 conversion [13].

"Beta-blockers remain the cornerstone of rate control for nearly all forms of tachycardia, with decades of mortality data supporting their use in both atrial fibrillation and heart failure," states the 2023 AHA/ACC/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation [11].

Side effects include fatigue, cold extremities, bradycardia, and bronchospasm. Non-selective agents (propranolol, nadolol) are relatively contraindicated in patients with reactive airway disease.

Calcium Channel Blockers for Rate Control

Non-dihydropyridine calcium channel blockers slow AV nodal conduction and serve as the primary alternative when beta-blockers are contraindicated or not tolerated. Diltiazem and verapamil are the two agents used for rate control. Dihydropyridine agents (amlodipine, nifedipine) do not slow the heart and may cause reflex tachycardia.

Intravenous diltiazem (0.25 mg/kg bolus over 2 minutes) reliably reduces ventricular rate in acute atrial fibrillation. A 2001 randomized trial (N=150) published in Annals of Emergency Medicine demonstrated that IV diltiazem achieved rate control (<100 bpm) in 75.8% of patients within 30 minutes, compared to 35.7% with IV metoprolol [14]. Oral diltiazem extended-release (120 to 360 mg daily) provides chronic rate control.

Verapamil carries stronger negative inotropic effects and should be avoided in patients with reduced ejection fraction (<40%). Both agents are contraindicated in combination with IV beta-blockers due to additive depression of cardiac conduction, which risks complete heart block.

Antiarrhythmic Drugs for Rhythm Control

When rate control alone is insufficient, antiarrhythmic drugs aim to restore and maintain normal sinus rhythm. These agents carry narrower therapeutic windows and more serious adverse effects than rate-control medications.

Adenosine is the first-line drug for acute SVT termination. Administered as a rapid IV push (6 mg, followed by 12 mg if ineffective), it transiently blocks the AV node. Success rates exceed 90% for AV nodal reentrant tachycardia (AVNRT) and AV reentrant tachycardia (AVRT) [3]. Patients experience a brief, uncomfortable sensation of chest tightness. The drug has a half-life of under 10 seconds.

Flecainide (50 to 150 mg twice daily) is a Class IC antiarrhythmic effective for maintaining sinus rhythm in atrial fibrillation patients with structurally normal hearts. The 2020 EAST-AFNET 4 trial (N=2,789) demonstrated that early rhythm control (including flecainide use) reduced a composite of cardiovascular death, stroke, and heart failure hospitalization by 21% compared to usual care over a median follow-up of 5.1 years [15]. Flecainide is contraindicated in patients with structural heart disease or coronary artery disease after the CAST trial showed increased mortality in post-myocardial infarction patients [16].

Amiodarone remains the most broadly effective antiarrhythmic, working across Class I, II, III, and IV mechanisms. It is the drug of choice for VT with a pulse (IV 150 mg over 10 minutes) and is recommended by the 2020 AHA ACLS algorithm for shock-refractory ventricular fibrillation [17]. Chronic oral dosing (100 to 200 mg daily after loading) maintains sinus rhythm in atrial fibrillation, but long-term use risks pulmonary toxicity (1 to 5% incidence), thyroid dysfunction (both hyper and hypothyroid), hepatotoxicity, and corneal microdeposits [18].

Dr. Hugh Calkins, Professor of Medicine at Johns Hopkins, has noted: "Amiodarone is uniquely effective but uniquely toxic. Every patient on chronic amiodarone needs serial thyroid function, liver function, and pulmonary function testing at minimum every six months" [18].

Dofetilide (125 to 500 mcg twice daily) is a pure Class III agent reserved for atrial fibrillation and atrial flutter. FDA labeling requires initiation during a 3-day inpatient stay with continuous QTc monitoring because of the risk of torsades de pointes. The SAFIRE-D trial (N=325) showed 58% of patients on dofetilide 500 mcg twice daily converted to sinus rhythm within 31 hours, versus 1.2% on placebo [19].

Ivabradine: A Targeted Heart Rate Reducer

Ivabradine selectively blocks the If ("funny") current in the SA node, slowing heart rate without affecting blood pressure, contractility, or AV conduction. The FDA approved it in 2015 for symptomatic heart failure with a resting rate at or above 70 bpm despite maximally tolerated beta-blocker therapy.

The SHIFT trial (N=6,558) demonstrated that ivabradine reduced the composite endpoint of cardiovascular death or heart failure hospitalization by 18% (HR 0.82, 95% CI 0.75 to 0.90, P<0.0001) in patients with heart failure and heart rates at or above 70 bpm [20]. Starting dose is 5 mg twice daily, titrated to a maximum of 7.5 mg twice daily.

Ivabradine is also used off-label for inappropriate sinus tachycardia (IST), a condition in which resting heart rate exceeds 100 bpm without identifiable cause. A 2017 prospective study (N=21) in Heart Rhythm found ivabradine reduced mean heart rate from 97 bpm to 78 bpm in IST patients who had failed beta-blocker therapy [21].

Drug-Induced Tachycardia: How to Respond

The management of drug-induced tachycardia follows a clear hierarchy: identify the causative agent, assess the clinical urgency, and either discontinue the drug, reduce the dose, or add a rate-controlling medication if the offending drug cannot be stopped.

For stimulant-induced tachycardia, the 2019 American Academy of Pediatrics clinical report on cardiovascular monitoring during stimulant therapy recommends checking heart rate and blood pressure at every visit, with a threshold for concern at a resting heart rate above 120 bpm or an increase of more than 20 bpm from baseline [22]. Dose reduction resolves the tachycardia in most cases. If the stimulant cannot be stopped (e.g., treatment-refractory ADHD), adding a low-dose beta-blocker is a common clinical strategy.

Levothyroxine-induced tachycardia requires TSH reassessment and dose reduction. The target TSH for most hypothyroid patients is 0.5 to 4.0 mIU/L, and palpitations typically resolve within 2 to 4 weeks of achieving a euthyroid level [7].

For clozapine-associated tachycardia, the Maudsley Prescribing Guidelines recommend monitoring resting heart rate weekly during the first 18 weeks of treatment [10]. Persistent tachycardia above 120 bpm warrants echocardiography to rule out myocarditis, a rare but life-threatening complication occurring in approximately 3% of clozapine-treated patients.

GLP-1 receptor agonist-induced heart rate increases are generally mild and not clinically actionable. The LEADER trial (N=9,340) found that liraglutide increased heart rate by 3 bpm on average but did not increase the incidence of major adverse cardiovascular events, and in fact reduced cardiovascular death by 22% [9].

When Rapid Heartbeat Requires Emergency Care

Not every episode of tachycardia is an emergency, but certain patterns demand immediate evaluation. Sustained ventricular tachycardia (>30 seconds or causing hemodynamic instability) is a medical emergency that requires cardioversion or IV antiarrhythmics. Wide-complex tachycardia on a 12-lead ECG should be treated as VT until proven otherwise.

Seek emergency care for:

• Resting heart rate above 150 bpm with lightheadedness, chest pain, or shortness of breath
• Syncope or near-syncope during a tachycardia episode
• New-onset irregular rapid heartbeat in patients on digoxin, antiarrhythmics, or QT-prolonging drugs
• Palpitations with signs of hemodynamic compromise (pallor, diaphoresis, altered mental status)

A 12-lead ECG is the single most important diagnostic tool. Narrow-complex tachycardia (<120 ms QRS) is almost always supraventricular in origin and carries a more favorable prognosis. Wide-complex tachycardia (>120 ms QRS) may be VT, SVT with aberrant conduction, or pre-excited tachycardia, and misclassification can lead to dangerous treatment errors [3].

Monitoring Heart Rate on Medication

Baseline and periodic heart rate monitoring is a simple but often overlooked practice that prevents drug-induced tachycardia from escalating. Wearable devices now provide continuous heart rate data. A 2022 study in JAMA Cardiology (N=419,297) found Apple Watch-based irregular rhythm notifications had a positive predictive value of 84% for atrial fibrillation detection when followed by confirmatory ECG patch [23].

For patients starting medications known to affect heart rate, the following monitoring schedule is practical:

• Beta-2 agonists (albuterol): check heart rate during acute exacerbation management; no routine monitoring needed for occasional use
• Stimulants (amphetamines, methylphenidate): heart rate and blood pressure at baseline, 1 month, and every visit thereafter
• Levothyroxine: TSH at 6 to 8 weeks after any dose change; heart rate at each office visit
• Clozapine: weekly heart rate for 18 weeks, then at each visit; troponin if tachycardia is persistent
• Amiodarone: TSH, LFTs, PFTs, and chest X-ray at baseline, then every 6 months
• GLP-1 agonists: heart rate at baseline and follow-up visits; no intervention needed for increases <10 bpm

Patients taking QT-prolonging medications (sotalol, dofetilide, certain antibiotics like azithromycin and fluoroquinolones) should have periodic ECGs to measure QTc interval, with a corrected QT above 500 ms warranting drug discontinuation or dose adjustment [24].